99-16417. Importation of Controlled Substances; Notice of Application  

  • [Federal Register Volume 64, Number 124 (Tuesday, June 29, 1999)]
    [Notices]
    [Pages 34825-34826]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 99-16417]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF JUSTICE
    
    Drug Enforcement Administration
    
    
    Importation of Controlled Substances; Notice of Application
    
        Pursuant to section 1008 of the Controlled Substances Import and 
    Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to 
    issuing a registration under this section to a bulk manufacturer of a 
    controlled substance in Schedule I or II and prior to issuing a 
    regulation under section 1002(a) authorizing the importation of such a 
    substance, provide manufacturers holding registrations for the bulk 
    manufacture of the substance an opportunity for a hearing.
        Therefore, in accordance with section 1301.34 of Title 21, Code of 
    Federal Regulations (CFR), notice is hereby given that on April 27, 
    1999, Radian International LLC, 14050 Summit Drive #121, P.O. Box 
    201088, Austin, Texas 78720-1088, made application by renewal to the 
    Drug Enforcement Administration to be registered as an importer of the 
    basic classes of controlled substances listed below:
    
    ------------------------------------------------------------------------
                        Drug                               Schedule
    ------------------------------------------------------------------------
    Cathinone (1235)............................  I
    Methcathinone (1237)........................  I
    N-Ethylamphetamine (1475)...................  I
    Ibogaine (7260).............................  I
    4-Bromo-2, 5-dimethoxyamphe- tamine (7391)..  I
    4-Bromo-2, 5-dimethoxyphenethyl- amine        I
     (7392).
    
    [[Page 34826]]
    
     
    4-Methyl-2, 5-dimethoxyamphe- tamine (7395).  I
    2, 5-Dimethozyamphe- tamine (7396)..........  I
    3, 4-Methylenediozyam- phetamine (7400).....  I
    3, 4-Methylenedioxy-N-ethylam- phetamine      I
     (7404).
    4-Methoxyamphetamine (7411).................  I
    Psilocybin (7437)...........................  I
    Psilocyn (7438).............................  I
    Etorphine (except HC1) (9056)...............  I
    Heroin (9200)...............................  I
    Pholcodine (9314)...........................  I
    Amphetamine (1100)..........................  II
    Methamphetamine (1105)......................  II
    Amobarbital (2125)..........................  II
    Pentobarbital (2270)........................  II
    Cocaine (9041)..............................  II
    Codeine (9050)..............................  II
    Dihydrocodeine (9120).......................  II
    Oxycodone (9143)............................  II
    Hydromorphone (9150)........................  II
    Benzoylecgonine (9180)......................  II
    Ethylmorphine (9190)........................  II
    Meperidine (9230)...........................  II
    Dextropropoxyphene, bulk (Non-dosage forms)   II
     (9273) ().
    Morphine (9300).............................  II
    Thebaine (9333).............................  II
    Levo-alphacetylmethadol (9648)..............  II
    Oxymorphone (9652)..........................  II
    ------------------------------------------------------------------------
    
        The firm plans to import small quantities of the listed controlled 
    substances for the manufacture of analytical reference standards.
        Any manufacturer holding, or applying for, registration as a bulk 
    manufacturer of these basic classes of controlled substances may file 
    written comments on or objections to the application described above 
    and may, at the same time, file a written request for a hearing on such 
    application in accordance with 21 CFR 1301.4 in such form as prescribed 
    by 21 FR 1316.47.
        Any such comments, objections, or requests for a hearing may be 
    addressed, in quintuplicate, to the Deputy Assistant Administrator, 
    Office of Diversion Control, Drug Enforcement Administration, United 
    States Department of Justice, Washington, D.C. 20537, Attention: DEA 
    Federal Register Representative (CCR), and must be filed no later than 
    (30 days from publication).
        This procedure is to be conducted simultaneously with and 
    independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
    (e), and (f). As noted in a previous notice at 40 F.R. 43745-46 
    (September 23, 1975), all applicants for registration to import the 
    basic classes of any controlled substances in Schedule I or II are and 
    will continue to be required to demonsrate to the Deputy Assistant 
    Administrator, Office of Diversion Control, Drug Enforcement 
    Administration that the requirements for such registration pursuant to 
    21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(a), (b), (c), 
    (d), (e), and (f) are satisfied.
    
        Dated June 10, 1999.
    John H. King,
    Deputy Assistant Administrator, Office of Diversion Control, Drug 
    Enforcement Administration.
    [FR Doc. 99-16417 Filed 6-28-99; 8:45 am]
    BILLING CODE 4410-09-M
    
    
    

Document Information

Published:
06/29/1999
Department:
Drug Enforcement Administration
Entry Type:
Notice
Document Number:
99-16417
Pages:
34825-34826 (2 pages)
PDF File:
99-16417.pdf